Cost-Effective Immunosuppressive Options for Solid Organ Transplantation: A Guide to Lower Cost for the Renal Transplant Recipient in the USA

• Ojo AO , PortFK, WolfeRA et al.: Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients.Am. J. Kidney Dis.24 , 59–64 (1994).
   PubMed Web of Science ®Google Scholar
• Oniscu GC , BrownH, ForsytheJL: Impact of cadaveric renal transplantation on survival in patients listed for transplantation.J. Am. Soc. Nephrol.16 , 1859–1865 (2005).
   PubMed Web of Science ®Google Scholar
• Wolfe RA , AshbyVB, MilfordEL et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.N. Engl. J. Med.341 , 1725–1730 (1999).
   PubMed Web of Science ®Google Scholar
• US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: 2005 Annual Report,Transplant Data 1995–2004. Health Resources and Services Administration, Healthcare Systems Bureau, Rockville, MD, USA (2005).
   Google Scholar
• Miller JT , CollinsCD, StuckeyLJ et al.: Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.Pharmacotherapy29 , 1166–1174 (2009).
   PubMed Web of Science ®Google Scholar
• Morton RL , HowardK, WebsterAC, WongG, CraigJC: The cost–effectiveness of induction immunosuppression in kidney transplantation.Nephrol. Dial. Transplant.24 , 2258–2269 (2009).
   PubMed Web of Science ®Google Scholar
• Farney A , SundbergA, MooreP et al.: A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.Clin. Transplant.22 , 41–49 (2008).
   PubMed Web of Science ®Google Scholar
• Farney AC , DoaresW, RogersJ et al.: A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.Transplantation88 , 810–819 (2009).
   PubMed Web of Science ®Google Scholar
• Ferguson RM , SommerBG: Cyclosporine in renal transplantation: a single institutional experience.Am. J. Kidney Dis.5 , 296–306 (1985).
   PubMed Web of Science ®Google Scholar
• Novick AC , BraunWE, SteinmullerD et al.: A controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation.Transplantation35 , 175–179 (1983).
   PubMed Web of Science ®Google Scholar
• Hardinger KL , BohlDL, SchnitzlerMA et al.: A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients.Transplantation80 , 41–46 (2005).
   PubMed Web of Science ®Google Scholar
• Lazzaro C , McKechnieT, McKennaM: Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost–effectiveness analyses.J. Nephrol.15 , 580–588 (2002).
   PubMed Web of Science ®Google Scholar
• Orme ME , JurewiczWA, KumarN, McKechnieTL: The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.Pharmacoeconomics21 , 1263–1276 (2003).
   PubMed Web of Science ®Google Scholar
• Gruessner RW , BurkeGW, StrattaR et al.: A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation.Transplantation61 , 261–273 (1996).
   PubMed Web of Science ®Google Scholar
• Lake JR , GormanKJ, EsquivelCO et al.: The impact of immunosuppressive regimens on the cost of liver transplantation – results from the U.S. FK506 multicenter trial.Transplantation60 , 1089–1095 (1995).
   PubMed Web of Science ®Google Scholar
• Kaufman DB , LeventhalJR, GallonLG, ParkerMA: Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction – long-term results.Am. J. Transplant.6 , 331–339 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman DB , LeventhalJR, AxelrodD et al.: Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term results.Am. J. Transplant.5 , 2539–2548 (2005).
   PubMed Web of Science ®Google Scholar
• McCarthy JM , KarimMA, KruegerH, KeownPA: The cost impact of cytomegalovirus disease in renal transplant recipients.Transplantation55 , 1277–1282 (1993).
   PubMed Web of Science ®Google Scholar
• Slifkin M , DoronS, SnydmanDR: Viral prophylaxis in organ transplant patients.Drugs64 , 2763–2792 (2004).
   PubMed Web of Science ®Google Scholar
• Abecassis MM , KoffronAJ, KaplanB et al.: The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?Transplantation63 , 275–279 (1997).
   PubMed Web of Science ®Google Scholar
• Walker JK , ScholzLM, ScheetzMH et al.: Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction.Transplantation83 , 874–882 (2007).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA , RichterA, AnnemansL, MaclaineG: Cost–effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.Pharmacoeconomics18 , 239–251 (2000).
   PubMed Web of Science ®Google Scholar
• Sabatini S , FergusonRM, HeldermanJH et al.: Drug substitution in transplantation: a National Kidney Foundation White Paper.Am. J. Kidney Dis.33 , 389–397 (1999).
   PubMed Web of Science ®Google Scholar
• Masri M : The generics in transplantation and the rules on their use.Exp. Clin. Transplant.1 , 65–68 (2003).
   PubMedGoogle Scholar
• Masri MA , AndrysekT, RizkS, MathaV: The role of generics in transplantation: TM-MMF versus Cellcept in healthy volunteers.Transplant. Proc.36 , 84–85 (2004).
   PubMed Web of Science ®Google Scholar
• Peet LB : Study looks at effectiveness of generics.Nephrol. News Issues17 , 68 (2003).
   PubMedGoogle Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant.9(Suppl. 3) , S1–S155 (2009).
   PubMed Web of Science ®Google Scholar
• el-Agroudy AE , SobhMA, HamdyAF, GhoneimMA: A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up.Transplantation77 , 1371–1376 (2004).
   PubMed Web of Science ®Google Scholar
• El-Dahshan KF , BakrMA, DoniaAF, Badr Ael S, Sobh MA: Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am. J. Nephrol.26 , 293–298 (2006).
   PubMed Web of Science ®Google Scholar
• Ciprandi G , AgostinisF, AmorosoS et al.: Economic evaluation of sublingual immunotherapy: an analysis of literature.Eur. Ann. Allergy Clin. Immunol.39 , 21–26 (2007).
   PubMedGoogle Scholar
• Cox LS , Larenas Linnemann D, Nolte H et al.: Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol.117 , 1021–1035 (2006).
   PubMed Web of Science ®Google Scholar
• Romero I , JimenezC, GilF et al.: Sublingual administration of tacrolimus in a renal transplant patient.J. Clin. Pharm. Ther.33 , 87–89 (2008).
   PubMed Web of Science ®Google Scholar
• Reams BD , PalmerSM: Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis.Am. J. Respir. Med.1 , 91–98 (2002).
   PubMedGoogle Scholar
• Kupin WL , VenkatKK, NorrisC et al.: Effective long-term immunosuppression maintained by low cyclosporine levels in primary cadaveric renal transplant recipients.Transplantation43 , 214–218 (1987).
   PubMed Web of Science ®Google Scholar
• Shapiro R , BasuA, TanH et al.: Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.J. Am. Coll. Surg.200 , 505–515; quiz A559–A561 (2005).
   PubMed Web of Science ®Google Scholar
• Page TF , WoodwardRS: Cost–effectiveness of Medicare‘s coverage of immunosuppression medications for kidney transplant recipients.Expert Rev. Pharmacoecon. Outcomes Res.9 , 435–444 (2009).
   PubMedGoogle Scholar
• Woodward RS , PageTF, SoaresR et al.: Income-related disparities in kidney transplant graft failures are eliminated by Medicare‘s immunosuppression coverage.Am. J. Transplant.8 , 2636–2646 (2008).
   PubMedGoogle Scholar
• Gruessner RW , SutherlandDE, DrangstveitMB et al.: Mycophenolate mofetil in pancreas transplantation.Transplantation66 , 318–323 (1998).
   PubMed Web of Science ®Google Scholar
• Knight SR , RussellNK, BarcenaL, MorrisPJ: Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review.Transplantation87 , 785–794 (2009).
   PubMed Web of Science ®Google Scholar
• Craig JC , WebsterAC, McDonaldSP: The case of azathioprine versus mycophenolate. Do different drugs really cause different transplant outcomes?Transplantation87 , 803–804 (2009).
   PubMed Web of Science ®Google Scholar
• Opelz G , DohlerB: Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.Transplantation87 , 795–802 (2009).
   PubMed Web of Science ®Google Scholar
• Varma PP , HoodaAK, KumarA, SinghL: Highly successful and low-cost desensitization regime for sensitized living donor renal transplant recipients.Ren. Fail.31 , 533–537 (2009).
   PubMed Web of Science ®Google Scholar
• Gheith OA , NematallaAH, BakrMA et al. Cost-benefit of steroid avoidance in renal transplant patients: a prospective randomized study. Scand. J. Urol. Nephrol. 44 , 175–182 (2010).
   PubMed Web of Science ®Google Scholar
• El-Agroudy AE , El-DahshanKF, WafaEW et al.: Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression.Nephrology (Carlton)14 , 255–261 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Transplant Living: Financing a Transplant(2010) www.transplantliving.org/beforethetransplant/finance/costs.aspx
   Google Scholar
• US Food and Drug Administration www.fda.gov
   Google Scholar